Decreased neutrophil-to-lymphocyte ratio predicted cognitive improvement in late-life depression treated with vortioxetine: Findings from an eight-week randomized controlled trial

被引:0
作者
Xue, Lingfeng [1 ]
Lewis, Elin [2 ]
Bocharova, Mariia [1 ]
Young, Allan H. [3 ]
Aarsland, Dag [1 ]
机构
[1] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Hlth Brain Ageing, London SE5 8AF, England
[2] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London SE5 8AF, England
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Affect Disorders, London SE5 8AF, England
关键词
Late-life depression; Vortioxetine; Neutrophil-to-lymphocyte ratio; Cognition; Inflammation; LU AA21004; ANTIDEPRESSANT TREATMENT; INFLAMMATORY MARKERS; PERIPHERAL CYTOKINE; PLATELET-LYMPHOCYTE; DOUBLE-BLIND; METAANALYSIS; SEVERITY;
D O I
10.1016/j.bbi.2025.01.029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Elevated neutrophil-to-lymphocyte ratio, a marker of inflammation, has been reported in adult and late-life depression. Vortioxetine has shown efficacy in treatment of late-life depression, yet little is known regarding its immunomodulatory role in clinical trials. Methods: This is a post-hoc analysis of an eight-week randomized controlled trial. Depressed patients aged 65 or above were treated by vortioxetine, duloxetine or placebo. 321 patients that have taken blood tests at baseline and endpoint were included in the analysis. Neutrophil-to-lymphocyte ratio (NLR) was calculated using the absolute counts of each cell type. Cognitive performance was assessed by composite score of Digit Symbol Substitution Test (DSST) and the Rey Auditory Verbal Learning Test (RAVLT) tasks, while depressive symptoms were assessed by Montgomery-& Aring;sberg Depression Rating Scale (MADRS) and Geriatric Depression Scale (GDS). Results: NLR levels decreased significantly in the entire analysis set (t(320) = 2.64, p = 0.008) and in the vortioxetine group (M = -0.186, t(105) = 2.070, p = 0.041, Cohen's d = 0.20), but not in the two other groups. This decrease was not significantly different compared to placebo (F(1, 213) = 0.420, p = 0.517). Furthermore, larger NLR changes in vortioxetine arm predicted significant cognitive improvement (3 = -4.03, p = 0.03), specifically regarding the DSST correct symbols (3 = -1.97, p = 0.04) and RAVLT delayed recall (3 = -1.87, p = 0.02) tasks. Additionally, decreased NLR significantly predicted reduced GDS score (3 = 1.82, p = 0.02), yet not MADRS score. Conclusion: Vortioxetine treatment was associated with decreased NLR levels in late-life depression, and reductions in NLR predicted improvements in cognitive function and depressive symptoms, suggesting a potential link between inflammation and clinical outcomes.
引用
收藏
页码:53 / 58
页数:6
相关论文
共 53 条
  • [1] Alboni S., Benatti C., Colliva C., Radighieri G., Blom J., Brunello N., Et al., Vortioxetine prevents lipopolysaccharide-induced memory impairment without inhibiting the initial inflammatory cascade, Front. Pharmacol., 11, (2021)
  • [2] Alvarez E., Perez V., Dragheim M., Loft H., Artigas F., A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder, Int. J. Neuropsychopharmacol., 15, 5, pp. 589-600, (2012)
  • [3] Bang-Andersen B., Ruhland T., Jorgensen M., Smith G., Frederiksen K., Jensen K.G., Et al., Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl) phenyl] piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder, J. Med. Chem., 54, 9, pp. 3206-3221, (2011)
  • [4] Bennett S., Thomas A.J., Depression and dementia: cause, consequence or coincidence?, Maturitas, 79, 2, pp. 184-190, (2014)
  • [5] Brinn A., Stone J., Neutrophil–lymphocyte ratio across psychiatric diagnoses: a cross-sectional study using electronic health records, BMJ Open, 10, 7, (2020)
  • [6] Capuron L., Miller A.H., Immune system to brain signaling: neuropsychopharmacological implications, Pharmacol. Ther., 130, 2, pp. 226-238, (2011)
  • [7] Chang H.H., Lee I.H., Gean P.W., Lee S.-Y., Chi M.H., Yang Y.K., Et al., Treatment response and cognitive impairment in major depression: association with C-reactive protein, Brain Behav. Immun., 26, 1, pp. 90-95, (2012)
  • [8] Chen X., Gianferante D., Hanlin L., Fiksdal A., Breines J.G., Thoma M.V., Et al., HPA-axis and inflammatory reactivity to acute stress is related with basal HPA-axis activity, Psychoneuroendocrinology, 78, pp. 168-176, (2017)
  • [9] Cheng Y., Wang Y., Wang X., Jiang Z., Zhu L., Fang S., Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in depression: an updated systematic review and meta-analysis, Front. Psych., 13, (2022)
  • [10] Conboy L., Varea E., Castro J.E., Sakouhi-Ouertatani H., Calandra T., Lashuel H.A., Et al., Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors, Mol. Psychiatry, 16, 5, pp. 533-547, (2011)